XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplementary Balance Sheet Information (Tables)
3 Months Ended
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]  
Schedule of Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

As of

 

 

 

March 31, 2024

 

 

December 31, 2023

 

Lab equipment

 

$

6,100

 

 

$

6,089

 

Leasehold improvements

 

 

26,262

 

 

 

24,713

 

Computer equipment

 

 

1,225

 

 

 

1,221

 

Furniture and fixtures

 

 

1,067

 

 

 

1,034

 

Software

 

 

325

 

 

 

325

 

Vehicles

 

 

97

 

 

 

97

 

Construction in process

 

 

32

 

 

 

 

 

 

35,108

 

 

 

33,479

 

Less accumulated depreciation

 

 

(6,533

)

 

 

(5,612

)

   Total property and equipment, net

 

$

28,575

 

 

$

27,867

 

Schedule of Intangible Assets, Excluding Goodwill

Intangible assets, excluding goodwill, consist of the following (in thousands):

 

 

March 31, 2024

 

 

December 31, 2023

 

 

 

Cost

 

 

Accumulated
Amortization

 

 

Net Carrying Value

 

 

Cost

 

 

Accumulated
Amortization

 

 

Net Carrying Value

 

Intangible assets subject to amortization

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patents

 

$

1,946

 

 

$

(782

)

 

$

1,164

 

 

$

1,975

 

 

$

(752

)

 

$

1,223

 

Purchased technology

 

 

16,900

 

 

 

(10,797

)

 

 

6,103

 

 

 

16,900

 

 

 

(10,328

)

 

 

6,572

 

Intangible assets not subject to
    amortization

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trademarks

 

 

117

 

 

 

 

 

 

117

 

 

 

116

 

 

 

 

 

 

116

 

   Total

 

$

18,963

 

 

$

(11,579

)

 

$

7,384

 

 

$

18,991

 

 

$

(11,080

)

 

$

7,911

 

Schedule of Future Estimated Amortization Expense of Intangible Assets

Future estimated amortization expense of intangible assets is (in thousands):

 

As of
March 31, 2024

 

Remainder of 2024

 

$

1,511

 

2025

 

 

2,011

 

2026

 

 

1,992

 

2027

 

 

1,033

 

2028

 

 

85

 

2029 and thereafter

 

 

635

 

Total

 

$

7,267

 

Schedule of Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

 

 

As of

 

 

 

March 31, 2024

 

 

December 31, 2023

 

Compensation related accruals

 

$

3,471

 

 

$

3,855

 

Accrued clinical trial expense

 

 

969

 

 

 

983

 

Other expenses

 

 

3,458

 

 

 

2,872

 

    Total accrued liabilities

 

$

7,898

 

 

$

7,710